Pharmafile Logo

Where translation falls short in practice

Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.

Man reading pamphlet

Running global clinical trials requires clear communication with participants. Every detail needs to land as intended. But a technically accurate translation may still fall short, creating avoidable barriers for participants and adding clarification burdens for site staff.

This is the gap between translated material and content that is genuinely understood. While standard translation focuses on linguistic accuracy, expert localisation adapts the meaning, context and tone so it works for the intended audience.

Accuracy does not guarantee understanding

So, what if the translation is technically correct but the participant still has to ask the site team what it really means? This is where localisation becomes essential.

It would be easy to assume a correctly translated sentence automatically conveys the intended meaning. In clinical research, this assumption can create challenges.

Before localisation even begins, we carefully craft the master document with the right tone, turning complex medical language into clear, plain English. Right from the start, this approach helps make our materials easier to understand. Once that solid foundation is set, our localisation experts adapt the content for each target language, making sure phrasing and sentence structures flow naturally while preserving the necessary medical accuracy. Ultimately, this process bridges the gap between technical correctness and real participant understanding.

How tone and intent shift across borders

Language is deeply tied to culture. What sounds polite and encouraging in one country might sound demanding or inappropriately casual in another.

For example, in some cultures, participant-facing materials are expected to use highly formal language, while in others a more conversational, approachable style is preferred. If materials written in plain English are directly translated without adapting the tone, they can come across as either too informal or overly authoritative, depending on the context. Localising content carefully adapts not just the words but the underlying intent, making sure it resonates with local expectations and, most importantly, helps foster participant trust.

Why right can still feel wrong

Even with perfect grammar, content can still feel unnatural. Best-practice research on translation and cultural adaptation in clinical studies has long shown that concepts and phrasing may need to be adapted, not just translated, to remain meaningful and relevant for the target audience. A recent study by Gregório et al. (2025) is one of many to evidence this.

Idiomatic expressions or metaphors used to explain how a drug works rarely cross borders intact. A ‘lock and key’ metaphor makes perfect sense to an English speaker, but it might have a totally different meaning in another region.

When trial participants read materials that feel distinctly foreign, they may question if the trial truly understands their needs. It’s vital that every piece of information reads as if it were written specifically for that local participant, in their own cultural context.

Spotting the warning signs

Poor translation can create operational challenges long before participants raise concerns directly. Trial teams may see the impact in added site queries, slower consent processes, misunderstandings around trial requirements and, over time, risks to protocol adherence and retention.

The value of getting it right

Standard translation gets your words across the border, but strategic localisation gets your meaning into the hands of the participant. We pride ourselves on delivering localised clinical trial materials that minimise confusion, reduce operational challenges and keep trials running smoothly.

Recognising where translation falls short is the first step. Next, we’ll look at what effective localisation actually looks like in practice.

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Cuttsy+Cuttsy welcomes new team members and celebrates a familiar face returning

Cuttsy+Cuttsy proudly announces the expansion of its team with the addition of three new hires—Michelle, Jay, and Emily—and the welcome return of former team member Sally as Account Director.

AI and away we go: key insights from Reuters Pharma 2025

AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.

Exciting updates from our content and strategy team

Cuttsy+Cuttsy celebrates new beginnings with the appointment of Oli Bailey as Strategy Director and recognises team excellence through several well-deserved promotions.

How is generative AI transforming clinical trials?

Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.

Content for all – how to connect with neurodiverse audiences

Discover essential strategies for crafting inclusive and accessible written content tailored for neurodivergent readers.

Cuttsy+Cuttsy launches ccura: AI powered, always human

Cuttsy+Cuttsy introduces ccura, an AI-powered healthcare communications platform that blends technology with human expertise to enhance collaboration, streamline workflows, and deliver patient-focused, high-quality solutions with security and compliance at its…

Two Sides of the Same Coin: Patient Engagement vs Patient Involvement

Unpack the difference between patient engagement and patient involvement.

Cuttsy+Cuttsy achieves Platinum accreditation from Investors in People

Cuttsy+Cuttsy is proud to have achieved a Platinum accreditation from Investors in People, placing them among the top 2% of organisations assessed globally.

Cuttsy+Cuttsy awarded Gold EcoVadis sustainability rating

Cuttsy+Cuttsy proudly announces their Gold Medal achievement from EcoVadis for 2024, placing them among the top 5% of companies assessed and within the 97th percentile, a testament to their unwavering…

Age is not just a number when it comes to clinical trials

In this blog we look at the critical underrepresentation of older adults in clinical trials, emphasising the need for inclusive trial designs and targeted strategies to ensure safe and effective…